NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

–European marketing authorization application on track in 2H25 – 

– PREVAIL Phase 3 CVOT remains on track –

– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) –

Read more at globenewswire.com